Small cell lung cancer (SCLC) accounts for approximately 10-15% of all cases. Chemotherapy with a platinum agent and etoposide remains the standard of care for limited -stage patients. In the past few years, several clinical trials have evaluated the efficacy of immunotherapy, ...
Small cell lung cancer: Treatment review. Respirology 11, 241-248. doi:10.1111/j.1440-1843.2006.00850.xCooper S, Spiro SG. Small cell lung cancer: Treatment review. Respirology 2006;11:241-8Cooper S, Spiro SG. Small cell lung cancer: treatment review. Respirology 2006;11:241-8....
Small-cell lung cancer is a highly malignant form of lung cancer, also known as oat-cell carcinoma, that accounts for approximately 15% of lung cancer cases. Composed of small, ovoid cells with very little cytoplasm, small-cell lung cancer usually originates in the bronchi and is caused by...
Small-cell lung cancer is an aggressive form of lung cancer and has been difficult to treat due to therapy resistance. This Review discusses challenges and recent advances in uncovering molecular changes that allow potentially efficient therapies. Small-
The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
The accurate diagnosis of small-cell lung cancer (SCLC) is crucial, as treatment strategies differ from those of other lung cancers. This systematic review aims to identify proteins differentially expressed in SCLC compared to normal lung tissue, evaluating their potential utility in diagnosing and pr...
Review article Lung Cancer 2021, Part 1 Thoracic Surgery Clinics Journal 2021,Thoracic Surgery Clinics AvgiLoizidouBSc, MBChB,EricLimMBChB, MSc, MD, FRCS(C-Th) Small cell lung canceris an aggressive form of cancer. Previously, surgery was rarely considered because most patients present at the ...
Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas...
Figure 1. Timeline of therapeutic development of immune checkpoint inhibitors in extensive disease (ED) small cell lung cancer (SCLC). CT, chemotherapy; tTMB, tissue tumor mutational burden [∗this is an agnostic approval in all tumors with high tTMB (≥10 mutations per megabase, mut/Mb) bas...
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, whic